mase-producing bacteria that inactivate piperacillin has decreased the clinical utility of this drug. One strategy used to counteract the problems associated with 3-lactamase-producing bacteria has been the development of ,-lactamase inhibitors such as clavulanic acid, sulbactam, and most recently, tazobactam (19) .
Tazobactam is a triazolymethyl penicillanic acid sulfone which possesses very little intrinsic antibacterial activity (14) . When tazobactam is combined with piperacillin, it significantly enhances the in vitro susceptibility of piperacillin against ,-lactamase-producing isolates of members of the family Enterobacteriaceae, Staphylococcus spp., and Bacteroides spp. (1, 7, 8, 10, 11, 13, 14, 16, 18, 25) .
Although the pharmacokinetic and pharmacodynamic parameters associated with optimal killing of gram-negative aerobic bacteria have been well characterized for P-lactam antibiotics (6) , strategies for the design of dosage regimens of ,-lactam-,-lactamase inhibitor combinations are not established. The question is relevant since dosage regimens of P-lactamase inhibitor combinations provide concentrations of inhibitor in vivo that exceed the breakpoint concentrations used in in vitro susceptibility testing of combinations for only 2 to 3 h.
The purpose of the study described here was to compare the pharmacodynamics of various dosage regimens of a fixed daily exposure of piperacillin alone and in combination with tazobactam against piperacillin-resistant or -susceptible bacteria in an in vitro model of infection.
MATERIALS AND METHODS
Bacteria. The following strains were studied: Pseudomonas aeruginosa ATCC 27853, a stable clinical isolate of methicillinsusceptible Staphylococcus aureus 7176 obtained from a patient with bacteremia, and an isogenic pair of Escherichia coli strains, the wild type (J53) and the transconjugant possessing the plasmid (J53.2-TEM-3) coding for the TEM-3 extended-spectrum P-lactamase (24) .
Susceptibility testing. Table 1 shows the MICs of piperacillin and piperacillin-tazobactam for the test strains. The strains were selected on the basis of their susceptibilities or resistance to piperacillin. E. coli J53.2-TEM-3 and S. aureus 7176 were piperacillin resistant, but all strains were susceptible to piperacillin-tazobactam (Table 1) . MICs were determined by the tube broth macrodilution method with an inoculum of -5 x 105 CFU/ml by standardized methods (21) . The 15 and 22% (7 to 15 determinations for each control). Experimental samples with drug concentrations greater than the ranges of the standards were diluted into the range of the curve. A one-compartment pharmacokinetic model was fit to drug concentrations in the central compartment measured following the first and last doses of both drugs for all regimens by using extended least-squares regression (MKMODEL, version 4; Biosoft, Milltown, N.J.).
Bacterial counts (CFU per milliliter) were determined by serially diluting the sample 10-fold in cold saline and inoculating it (in triplicate) onto drug-free Mueller-Hinton agar (MHA) with subsequent incubation at 37°C for 18 to 24 h. The pharmacokinetics of the drugs in the model and the sampling schedule resulted in little or no carryover of drug. The most drug that was carried over during the processing for CFU per milliliter counts was 7.5 mg of piperacillin per liter in experiments with piperacillin alone against piperacillin-resistant bacteria; in view of the high MICs for these strains (128 mg/liter), this amount would have a negligible effect on the recovery of bacteria. Small numbers of bacteria (i.e., .1,000 CFU/ml) were counted by placing 100 ,ul of sample into -10 ml of cold saline and filtering this mixture through a 0.45-,um-pore-size filter (Millipore Corporation, Bedford, Mass.). The filter was washed several times with sterile saline and was then placed directly onto MHA and incubated, and the colonies were counted; thus, the theoretical limit of detection for this method is 10 CFU/ml. The dilution of the sample into saline and washing with an additional 5 to 10 ml makes it unlikely that significant amounts of drug are transferred with bacteria on the filter to MHA. In all experiments, samples collected at 0 and 24 h were also processed on MHA containing 128 jig of piperacillin per ml and 128 and 4 ,ug of piperacillin-tazobactam per ml, respectively, to quantify drug-resistant bacterial subpopula- Table 2 . In experiments that assessed the pharmacodynamics of piperacillin given as 3 g every 6 h against piperacillin-resistant bacteria, the piperacillin concentrations measured in the central and peripheral compartments were lower than targeted concentrations but still within acceptable ranges (data not shown). This was expected, however, because of bacterial production of ,-lactamase and the inactivation of piperacillin, which led to "sink" conditions in the model. For marked bactericidal effect; on average, a 4-log-unit reduction in the number of CFU per milliliter occurred within the first dosing interval (Fig. 2A) . Mean bacterial counts of -10 CFU/ml were achieved with all regimens by the end of the second dosing interval. There was no difference in bacterial killing with either regimen of piperacillin-tazobactam from that observed with piperacillin monotherapy.
Experiments with piperacillin alone against E. coli J53-TEM-3 showed the effect of the inactivating enzyme on pharmacodynamic properties (Fig. 2B) . Although E. coli J53-TEM-3 was resistant, the piperacillin MIC for the strain was exceedec in the model for -2 h, thus resulting in only transient bacterial killing and then the regrowth of bacteria fully resistant to the piperacillin concentrations obtained in the model. The numbers of bacteria recovered on drug-free MHA and MHA with 128 mg of piperacillin per liter were identical.
The addition of tazobactam to piperacillin restored the bacterial killing of the ,B-lactamase-producing isogenic strain of E. coli (J53.2-TEM-3) by piperacillin to that observed with the parent strain (Fig. 2B) . There was no difference in bacterial killing when the fixed daily exposure of piperacillin-tazobactam was fractionated into dosing intervals of every 6 or 8 h. When samples collected at 24 h from the piperacillin monotherapy experiment were grown on drug-containing MHA to quantify drug-resistant subpopulations, the entire inoculum was resistant to 128 ,ug of piperacillin per ml; however, no growth was seen on plates containing 128 and 4 ,ug of piperacillin and tazobactam per ml, respectively. The MICs for posttreatment bacteria (24 (B) in an in vitro model of infection. Datum points are geometric means ± standard deviations for three to six within-day replications. The regimens were piperacillin given as 3 g every 6 h (q6h) (A), piperacillin and tazobactam given as 3 and 0.375 g, respectively, every 6 h (q6h) (V), and piperacillin and tazobactam given as 4 and 0.5 g, respectively, every 8 h (q8h) (0). per milliliter over 2 h; this was followed by bacterial regrowth (Fig. 3A) . In contrast, both piperacillin-tazobactam regimens were highly active against this strain. There was no difference in bacterial killing when the fixed daily exposure of piperacillin-tazobactam was fractionated into dosing intervals of every 6 and 8 h. Subpopulation analysis and the posttreatment MICs obtained from the piperacillin monotherapy experiment were comparable to the results obtained for the other P-lactamaseproducing strain.
(iii) P. aeruginosa ATCC 27853. All regimens of piperacillin alone or combined with tazobactam resulted in a 4-log-unit reduction in the number of CFU per milliliter during the first dosing interval (Fig. 3B) . As was seen with E. coli J53, the addition of tazobactam had no effect on piperacillin pharmacodynamics. Killing was fairly consistent between regimens until the 14-h time point, when 2 log units of bacterial regrowth occurred with the piperacillin monotherapy regimen. When samples collected at 24 h from the piperacillin monotherapy experiment were grown on MHA containing 128 ,ug of piperacillin per ml no growth occurred. The MICs for posttreatment bacteria recovered on drug-free MHA were unchanged.
DISCUSSION
When using 3-lactamase inhibitor combinations, it is important that an adequate amount of inhibitor be provided in vivo to inactivate the 13-lactamases produced by actively growing bacteria at the site of infection. Livermore (15) has proposed that the activities of various ,B-lactam-3-lactamase inhibitor combinations be determined by assessment of the concentration of inhibitor required to bring the susceptibilities of individual organisms to below accepted susceptibility breakpoints for the ,-lactam alone or even to the susceptibilities for 3-lactamase-negative, wild-type strains. Since inactivation of ,-lactamases follows stoichiometry on the basis of turnover of the enzyme, the amount of [3-lactamase inhibitor necessary to augment the activity of a P-lactam in vivo would be based on the provision of an adequate amount of inhibitor provided over time, or the AUC. Failure to deliver adequate amounts of inhibitor would be expected to result in resistance to the drug combination, including bacterial regrowth at the end of a dosage interval. Resistance to 1-lactam-P-lactamase inhibitor combinations has been described in certain strains of E. coli that hyperproduce the TEM-1 1-lactamase, and hence have a relative insufficiency of inhibitor (15, 16) .
The results of the present study indicate that a simulated fixed daily exposure of piperacillin-tazobactam given as divided doses every 6 or 8 h results in similar pharmacodynamic effects against a piperacillin-resistant E. coli strain and S. aureus in the model. Despite extended periods of concentrations of tazobactam less than the fixed concentration used in in vitro susceptibility testing (4 mg/liter), the bactericidal activity of piperacillin-tazobactam against TEM-3-producing E. coli was similar to that observed for piperacillin monotherapy against ,B-lactamase-negative E. coli J53.
The prolonged bactericidal effects of the combination greater than the amount of inhibitor that is available during incubation during susceptibility testing. This exposure profile was sufficient to enable bacterial killing by piperacillin in the model similar to that observed for the ,B-lactamase-negative isogenic strain. It appears that in vivo the AUC for an inhibitor is the important parameter for the activities of combinations with 3-lactamase inhibitors against ,B-lactamase-producing bacteria. Thus, it is possible to prolong the dosage interval of a ,B-lactam-P-lactamase inhibitor combination for a finite period that is limited by the reaccumulation of the ,-lactamase produced by persisting bacteria to levels that exceed the number of molecules of an inhibitor available to inactivate the ,-lactamase.
The strategy of using prolonged dosage intervals of inhibitor combinations may not apply in all cases. Others have shown the rapid regrowth of bacteria in vitro after exposure to ticarcillin-clavulanic acid, removal of clavulanic acid, and resuspension in ticarcillin alone (9) . Some strains with multiple copies of plasmids that hyperproduce ,B-lactamase or combinations of inhibitors with more labile 3-lactams may not be amenable to prolonged inhibition of growth with extended dosage intervals.
The results of the present study show that the combination of piperacillin-tazobactam given as a daily exposure of 12 g of piperacillin and 1.5 g of tazobactam fractionated into dosage intervals of every 6 or 8 h resulted in similar degrees of bacterial killing under conditions that simulated the pharmacokinetics in humans in the in vitro model of infection used in the study. These results are concordant with human studies of 4 g of piperacillin plus 0.5 g of tazobactam every 8 h to patients with intra-abdominal infections, lower respiratory tract infections, and skin and soft-tissue infections (3, 20, 26) and suggest that further clinical evaluation of extended dosage intervals of this combination in humans is warranted.
